**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 54479

**Manuscript Type:** MINIREVIEWS

**Functions and mechanisms of chemokine receptor 7 in tumors of the digestive system**

Xin Q *et al*. Chemokine receptor 7 in tumor of digestive system

Qi Xin, Quan Sun, Chuan-Shan Zhang, Qin Zhang, Chun-Jun Li

**Qi Xin,** **Chuan-Shan Zhang, Qin Zhang,** Department of pathology, Tianjin third central hospital, The Third Central clinical college of Tianjin Medical University, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Tianjin 300170, China

**Qi Xin,** Tianjin Key Laboratory of Brain Science and Neural Engineering, Academy of Medical Engineering and Translational Medicine, Tianjin University, Tianjin 300072, China

**Quan Sun,** Department of hepatobiliary surgery, Tianjin third central hospital, The Third Central clinical college of Tianjin Medical University, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Tianjin 300170, China

**Chun-Jun Li,** Department of Endocrinology, Health Management Center, Tianjin Union Medical Center, Nankai University Affiliated Hospital, Tianjin 300121, China

**Author contributions:** Xin Q and Li CJ wrote the main text; Li CJ, Zhang CS and Zhang Q conceptualized the manuscript; Li CJ and Xin Q designed and generated the figures; Sun Q researched content for the review, discussed the content, and edited the manuscript.

**Supported by** Key Projects of Tianjin Natural Science Foundation, No. 19JCZDJC36100; General Project of Natural Science Fund of Tianjin Education Commission, No. 2018KJ047; Subject in the Third Affiliated Central Hospital of Nankai University, No. 2017YNY3; Tianjin Key Special Projects, No. 15KG115.

**Corresponding author: Chun-Jun Li**, **PhD, Chief Doctor,** Department of Endocrinology, Health Management Center, Tianjin Union Medical Center, Nankai University Affiliated Hospital, 190 Jai-yuan Road, Hong-qiao District, Tianjin 300121, China. [li\_chunjun@126.com](mailto:li_chunjun@126.com)

**Received:** February 2, 2020

**Revised:** May 12, 2020

**Accepted:** June 3, 2020

**Published online:**

**Abstract**

Chemokine (C-X-C motif) receptor 7 (CXCR7), recently termed ACKR3, belongs to the G protein-coupled cell surface receptor family, binds to stromal cell-derived factor-1 [SDF-1, or chemokine (C-X-C motif) ligand 12] or chemokine (C-X-C motif) ligand 11, and is the most common chemokine receptor expressed in a variety of cancer cells. SDF-1 binds to its receptor chemokine (C-X-C motif) receptor 4 (CXCR4) and regulates cell proliferation, survival, angiogenesis and migration. In recent years, another new receptor for SDF-1, CXCR7, has been discovered, and CXCR7 has also been found to be expressed in a variety of tumor cells and tumor-related vascular endothelial cells. Many studies have shown that CXCR7 can promote the growth and metastasis of a variety of malignant tumor cells. Unlike CXCR4, CXCR7 exhibits a slight modification in the DRYLAIV motif and does not induce intracellular Ca2+ release following ligand binding, which is essential for recruiting and activating G proteins. CXCR7 is generally thought to work in three ways: (1) Recruiting β-arrestin 2; (2) Heterodimerizing with CXCR4; and (3) Acting as a “scavenger” of SDF-1, thus lowering the level of SDF-1 to weaken the activity of CXCR4. In the present review, the expression and role of CXCR7, as well as its prognosis in cancers of the digestive system, were investigated.

**Key words:** Stromal cell-derived factor-1; Chemokine (C-X-C motif) receptor 7; Chemokine (C-X-C motif) receptor 4; Carcinoma; Digestive system

Xin Q, Sun Q, Zhang CS, Zhang Q, Li CJ. Functions and mechanisms of chemokine receptor 7 in tumors of the digestive system. *World J Clin Cases* 2020; In press

**Core tip:** Digestive tract tumors are one of the most important tumors in the whole body. As a newly discovered receptor of stromal cell-derived factor-1, chemokine (C-X-C motif) receptor 7 (CXCR7) has attracted increasing attention from researchers. Over the years, studies have found that CXCR7 is expressed in a variety of malignant tumors of the digestive system and plays an important role in the occurrence, development and metastasis of tumors. Many studies have also shown that CXCR7 can serve as a prognostic factor for a variety of tumors and may be a target for the treatment of a variety of tumors. Here, we summarized all the manifestations and functions of CXCR7 in various gastrointestinal tumors and compared the research status of CXCR7 in different types of gastrointestinal tumors.

**INTRODUCTION**

Chemokines are an almost 50-member group of small peptide proteins secreted by various cell types after induction, and they bind to chemokine receptors[[1](#_ENREF_1)]. Chemokines play crucial roles in many physiological and pathological processes. They also play an important role in the tumorigenesis, migration, proliferation, angiogenesis, survival and progression of tumors. The configuration of the two cysteines closest to the N-terminus allows chemokines to be split into four subfamilies: CC, CXC, CX3C and XC. Chemokines have a highly conserved tertiary structure that consists of a free N-terminus followed by a three-stranded β-sheet with an embedded C-terminal α-helix. Chemokines work by binding to the specifically paired G protein-coupled 7 transmembrane domain receptor, causing phosphorylation of serine and threonine residues at the C-terminal of the intracellular receptor and causing intracellular signal transduction.

Stromal cell-derived factor-1 (SDF-1) is a member of the CXC chemokine subfamily and is secreted by bone marrow stromal cells, endothelial cells, stromal fibroblasts and hepatic stellate cells[[2](#_ENREF_2)]. SDF-1 plays an important role in hematopoietic, cardiovascular, nervous system and other physiological states, and regulates a variety of cellular functions in the immune system, including differentiation, distribution, activation, immune synapse formation, effector function, proliferation and survival. In addition to playing an important role in physiological processes, SDF-1 is also involved in pathological processes involved in the occurrence of disease development. This process is known to promote tumor growth and metastasis in at least 20 malignancies[[3-5](#_ENREF_3)]. The G protein-coupled receptor chemokine (C-X-C motif) receptor 4 (CXCR4) has been considered for many years as the only receptor for SDF-1. Chemokine (C-X-C motif) receptor 7 (CXCR7), which belongs to the G protein-coupled cell surface receptor family, binds to SDF-1 with even higher affinity than CXCR4 and is the most common chemokine receptor expressed in a variety of cancer cells. Unlike CXCR4, CXCR7 exhibits a slight modification in the DRYLAIV motif and does not induce intracellular Ca2+ release following ligand binding, which is essential for recruiting and activating G proteins[[6](#_ENREF_6)]. CXCR7 is a nonclassical G protein coupled receptor that is unable to activate G proteins. Early work suggested that CXCR7 is a scavenger receptor that creates gradients of SDF-1 to influence cell migration through SDF-1-CXCR7 internalization[[7](#_ENREF_7)]. After binding with CXCR7, SDF-1 is internalized into the cytoplasm to cause signal transduction. After that, SDF-1 is transported to lysosomes for degradation, causing the difference in the concentration of SDF-1 inside and outside the cell, and CXCR7 is circulated to the cell membrane again[[8](#_ENREF_8),[9](#_ENREF_9)]. Like CXCR4, CXCR7 is constitutively internalized and recycled between the cell membrane and endosomes in the cytoplasm, leading to higher intracellular concentrations than what is expressed on the plasma membrane, a dynamic and periodic process of regulating the levels of extracellular SDF-1 and the expression of CXCR4. The endosomal recycling of CXCR7 is less affected by SDF-1 concentrations than by CXCR4 concentrations; however, CXCR4 cell surface expression decreases by up to 50% under higher SDF-1 conditions. Further research into CXCR7 alternative signaling has challenged this thinking. Evidence has shown that CXCR7 binding of SDF-1 causes non-G protein-mediated β-arrestin accumulation and subsequent extracellular regulated protein kinases (ERK) activation *via* mitogen-activated protein kinases (MAPK), which potentiate SDF-1-mediated downstream signaling[[10](#_ENREF_10)]. CXCR7 is not expressed or weakly expressed in most normal tissues, but it is highly expressed in many cancer tissues, including cancers of the prostate, lung, liver, colon and pancreas[[11-13](#_ENREF_11)]. More importantly, the presence of CXCR7 is necessary for cancer cell survival, migration, adhesion, angiogenesis and metastasis[[14](#_ENREF_14),[15](#_ENREF_15)]. The interaction between SDF-1 and CXCR7 was shown to induce cellular adhesion, proliferation and survival *in vitro* and *in vivo*[[16](#_ENREF_16)]. Because CXCR7 expression has been associated with tumor aggressiveness, our previous studies showed that high expression of CXCR7 can promote lymph node and liver metastasis of gastric cancer[[17](#_ENREF_17)] and also predict a poor prognosis[[3](#_ENREF_3),[18](#_ENREF_18)].

In different types of tumor cells, affected by differentiation and microenvironment, CXCR4 and CXCR7 can be expressed uniquely or in combination[[19](#_ENREF_19)]. When only CXCR7 is expressed in cells, SDF-1 binds to CXCR7 to activate intracellular signals by recruiting β-arrestin[[20](#_ENREF_20)]. When CXCR4 and CXCR7 are co-expressed, CXCR4 and CXCR7 can form homodimers or heterodimers[[21](#_ENREF_21),[22](#_ENREF_22)]. Previous literature along with our forthcoming research results show that in the process of tumor development, heterodimers seems to play a more important role, especially in regulating the signaling cascade downstream of cancer cells[[23](#_ENREF_23)]. Whether CXCR4 or CXCR7 is expressed alone, it results in little activation of the p38 MAPK and stress-activated protein kinase (SAPK) pathways. However, cells co-expressing both CXCR4 and CXCR7 showed increased levels of phosphorylated p38 MAPK and SAPK upon SDF-1 stimulation[[22](#_ENREF_22)]. With heterodimerization, Gαi signaling is modified, intracellular calcium release is decreased and β-arrestin signaling is increased[[21](#_ENREF_21)]. CXCR4/CXCR7 forms heterodimers and recruits β-arrestin to form CXCR4/CXCR7/β-arrestin complex[[21](#_ENREF_21)]. More downstream effects of the CXCR4/CXCR7/β-arrestin complex include prolonged ERK1/2 and p38 MAPK signaling and increased chemotaxis towards SDF-1[[22](#_ENREF_22)]. Co-expression of CXCR7 and CXCR4 not only can synergistically enhance the recruitment of β-arrestin and activate ERK1/2 MAPK pathway to cause invasion and metastasis but can also inhibit CXCR4-mediated phosphatidylinositol-3-phosphate (PI3K)/MAPK signaling pathway through CXCR7 competitively binding SDF-1[[22](#_ENREF_22),[24](#_ENREF_24)]. There may also be crosstalk between CXCR4 and CXCR7 upon ligand binding that is mediated by intracellular signaling effectors[[25](#_ENREF_25)]. CXCR7 is generally thought to work in three ways: (1) Recruiting β-arrestin 2[[10](#_ENREF_10)]; (2) Heterodimerizing with CXCR4[[21](#_ENREF_21)]; and (3) Acting as a “scavenger” of SDF-1, thus lowering the level of SDF-1 to weaken the activity of CXCR4[[26](#_ENREF_26),[27](#_ENREF_27)].

CXCR7 also binds to CXCL11, another chemokine family member; CXCR7 may also recruit CXCR4 when it has bound CXCL11 or different CXCR4 ligands or vice versa[[19](#_ENREF_19)]. However, the results from a large number of studies show that SDF-1/CXCR7 signaling plays an important role in many physiological and pathological processes. Herein, we will review the effects of CXCR7 in digestive tract tumor development and progression as well as the potential of targeting this pathway for cancer therapy. Considerable efforts have been made in recent years to elucidate the biological function of chemokine receptors in cancer development and metastasis. So far, the role of CXCR7 in various types of tumors of the digestive system remains unclear. Even in the same type of tumors, the results of different studies vary. Table 1[28-60] provides a 10-year literature review of CXCR7 in digestive tumors.

**ESOPHAGEAL CANCER**

***Expression in tumor tissue***

CXCR7 is expressed in the cytoplasm and membrane of esophageal cancer cells[[29](#_ENREF_29)], and CXCR7 expression is rarely found in esophageal adenocarcinomas but is overexpressed in almost half of esophageal squamous cell carcinomas (ESCC)[[30](#_ENREF_30),[61](#_ENREF_61)]. CXCR7 expression was significantly higher in ESCC tissues than in paired noncancerous tissues. In addition, the expression of CXCX7 in chemotherapy-sensitive ESCC patients is significantly lower than that in patients with chemotherapy-resistance[[32](#_ENREF_32)].

***CXCR7 in the development and metastasis***

The high expression of CXCR7 was closely associated with higher histological grade and advanced clinical stage in patients with ESCC[[29](#_ENREF_29)]. However, there was also a finding that the expression of CXCR7 in ESCC was unrelated to growth and metastasis[[30](#_ENREF_30)]. After silencing CXCR7 in esophageal cancer cell lines (TE-1, EC9706 and EC109), it was found that silencing CXCR7 inhibited the apoptosis and chemotaxis of esophageal cancer cells, and *in vivo* animal experiments showed that CXCR7 could promote the growth of esophageal cancer through, and ERK1/2 pathway activation[[29](#_ENREF_29)]. Interleukin (IL)-6 is an upstream regulator of CXCR7. By upregulating the expression of CXCR7, promoting the proliferation of tumor cells and drug resistance is an important way for it to interfere with tumors[[32](#_ENREF_32)]. Hypermethylated in cancer Ι (HIC1) is a direct repressor of the CXCR7 gene. In esophageal cancer patients lacking HIC1 expression, overexpressed CXCR7 can promote tumor growth[[61](#_ENREF_61)].

***Role of CXCR7 in tumor prognosis***

So far, there is substantial evidence that CXCR7 plays a crucial role in indicating poor prognosis of cancer patients. Patients with esophageal squamous cell carcinoma with high expression of CXCR7 have significantly worse overall survival (OS) and progression-free survival (PFS) after cisplatin chemotherapy than patients with low expression of CXCR7[[29](#_ENREF_29),[32](#_ENREF_32)]. However, it remains controversial because contradictory evidence has also been reported. For example, the expression of CXCR7 had no effect on the survival and prognosis of patients with esophageal squamous cell carcinoma or adenocarcinoma[[30](#_ENREF_30)].

**GASTRIC CANCER**

***Expression in tumor tissue***

CXCR7 expression was detected at the mRNA and protein levels in five types of gastric cancer cell lines (HGC-27, MGC-803, BGC-823, SGC-7901 and MKN-28) by reverse transcription-polymerase chain reaction and Western blotting[[4](#_ENREF_4)]. The mRNA and protein expression levels of CXCR7 were the most obvious in SGC-7901 cells, which had higher levels of CXCR7 than CXCR4[[31](#_ENREF_31)] (Table 2)[62].

CXCR7 is expressed in the cell membrane or cytoplasm in gastric cancer cells[[17](#_ENREF_17),[31](#_ENREF_31)]. Our team's previous research found that the expression of CXCR7 in gastric cancer tissues was significantly higher than that in surrounding non-tumor tissues, and it was also expressed in some mesenchymal cells and inflammatory cells of tumor tissues[[17](#_ENREF_17)]. Our previous studies showed that CXCR7 expression was seen in tumor-associated blood vessels in gastric cancer tissues, and CXCR7 expression was not seen in normal vascular endothelium at non-tumor sites. In addition, the expression of CXCR7 in cancer cells in metastatic vessels is significantly stronger than that in primary gastric cancer cells[[17](#_ENREF_17)].

***CXCR7 in the development and metastasis***

CXCR7 promotes the proliferation, adhesion, migration, invasion and metastasis of gastric cancer cells through β-arrestin-dependent downstream signaling[[31](#_ENREF_31)], Akt (PKB, also known as including protein kinase B), ERK1/2, p38 MAPK, just another kinase/serial advanced technology attachment/cellular-myelocytomatosis (JAK2/STAT3/c-Myc) and SAPK pathways, by combining with SDF-1[[4](#_ENREF_4),[17](#_ENREF_17),[34](#_ENREF_34)]. CXCR7 inhibits the processing of poly ADP-ribose polymerase and caspase-3 and induces an anti-apoptotic effect[[34](#_ENREF_34)]. CXCR7 promotes the proliferation of gastric cancer BGC803 cells by being negatively regulated by miR-100[[63](#_ENREF_63)]. Downregulation of CXCR7 significantly inhibits tumor growth *in vivo*[[31](#_ENREF_31)]. Gastric cancer cells with high expression of CXCR7 are directed to specific target organs along the concentration gradient formed by SDF-1, and CXCR7 can promote the lymph node and liver metastasis of gastric cancer[[17](#_ENREF_17)]. CXCR7 may also be associated with peritoneal metastasis in gastric cancer; high CXCR7 mRNA expression is associated with a high risk of peritoneal metastasis[[31](#_ENREF_31)]. Lipopolysaccharide (LPS) is a toxic component of the outermost dermis of *Helicobacter pylori* cells, which can cause long-term inflammatory damage to the gastric mucosa[[35](#_ENREF_35)]. The expression of Toll-like receptor 4 (TLR4) and CXCR7 is related to the growth and metastatic potential of gastric cancer, because LPS can upregulate the expression of CXCR7 through TLR4 signal and promote the proliferation and migration of gastric cancer cells. Myeloid differentiation factor 2 (MD-2) is a receptor molecule necessary for LPS-mediated activation of the TLR4 transmembrane signaling pathway and an important regulator of innate immune recognition. In LPS-induced gastric cancer, CXCR7 regulates downstream molecules through TLR4/MD-2 signaling to promote tumor development[[35](#_ENREF_35)]. CXCR7 can serve as a factor in the regulation of vascular endothelial growth factor (VEGF) secretion and induce angiogenesis in gastric cancer[[4](#_ENREF_4),[31](#_ENREF_31)]. Elevated CXCR7 expression levels are related to peritoneal metastasis and worse prognosis in gastric tumor patients[[32](#_ENREF_32)]. The mechanism of CXCR7 in gastric cancer cell is shown in Figure 1.

**HEPATOCELLULAR CARCINOMA**

***Expression in tumor tissue***

Hepatocellular carcinoma (HCC) cells (HCCLM3, SMMC‑7721, L02, QSG7701, MHCC97‑L, HepG2, Huh7, SNU449, 97H, LM3, QGY-7703, Hep3B, LM6 and SNU475) expressed CXCR7[[48](#_ENREF_48),[49](#_ENREF_49),[53](#_ENREF_53)], and highly metastatic cells (MHCC97‑L, 97H, LM3 and LM6) expressed much higher levels of CXCR7 than low-metastasis cells, including QGY-7703, HepG2 and Hep3B[[53](#_ENREF_53)]. Moreover, CXCR7 was more markedly unregulated in the HCCLM3 cell line than in the MHCC97-L and SMMC‑7721 cell lines[[49](#_ENREF_49)] (Table 2).

CXCR7 is stained mainly in the membrane and cytoplasm of HCC, with a positivity rate of 63%-85% by immunohistochemistry[[52](#_ENREF_52),[54](#_ENREF_54)]. In the HCC group, CXCR7 levels were five times higher than those in normal hepatocytes[[49](#_ENREF_49),[53](#_ENREF_53)]. High CXCR7 expression has been found in metastatic HCC samples and in the majority of tumor-associated vessels and is related to tumor neovascularization[[49](#_ENREF_49)]. CXCR7 expression can be seen in almost all vascular endothelium in HCC, but CXCR7 expression is hardly seen in the vascular endothelium of normal liver tissues adjacent to the cancer. Very interestingly, in addition to the strong positive expression of CXCR7 on HCC, the expression of CXCR7 can also be seen in the vascular endothelium of liver cirrhosis around the cancer tissue[[52](#_ENREF_52)].

***CXCR7 in the development and metastasis***

CXCR7 can promote tumorigenesis, growth and metastasis of HCC[[15](#_ENREF_15),[49](#_ENREF_49),[53](#_ENREF_53)]. The knockdown of CXCR7 inhibits HCC growth in mice after transcatheter hepatic arterial chemoembolization (TACE)[[15](#_ENREF_15)]. Elevated CXCR7 promotes cell proliferation by serving as a cell cycle priming factor in that it induces the G0/G1 to S phase transition in HCC[[53](#_ENREF_53)]. CXCR7 contributes to HCC growth by regulating phosphorylation on ERK1/2 at Thr202/Tyr203, p38 at Thr180/Tyr183 and SAPK/Jun kinase enzyme at Thr183/Tyr185 and invasiveness *via* the promotion of matrix metalloproteinase (MMP) 2 expression[[15](#_ENREF_15)]. Treatment with the CXCR7 antagonist CCX771 significantly reduces the formation of phosphorylated ERK[[53](#_ENREF_53)]. The orthotopic transplantation model found that CXCR7 affects lymphocytes entering the liver or intestine, and CXCR7 downregulation reduces SDF-1 levels in the bloodstream of mice, indicating that CXCR7 can regulate SDF-1 levels and have proinflammatory effects[[53](#_ENREF_53)]. CXCR7 is closely associated with the differentiation of HCC. Activated CXCR7 can inhibit the transcription factor hepatocyte nuclear factor 4 by activating the ERK signaling pathway, thus causing the dedifferentiation of HCC. The CXCR7-MAPK-hepatocyte nuclear factor 4α cascade is the main pathway for the differentiation of HCC cells[[51](#_ENREF_51)].

The lung is the most common site of distant metastasis of HCC. CXCR7 is a potential prognostic factor for lung metastasis of HCC, and a group with high expression of CXCR7 had a 1.6 times greater chance of lung metastasis than a group with low expression of CXCR7[[49](#_ENREF_49),[52](#_ENREF_52)]. The group with high expression of CXCR7 showed a prominent short-term development of lung metastasis compared with the group with low expression of CXCR7, especially during the early stage of follow-up. The knockdown of CXCR7 inhibited lung metastasis of HCC in mice after TACE[[15](#_ENREF_15)]. Although metastasis was unlikely to occur in well-differentiated HCC patients, metastasis was also likely to occur if CXCR7 was highly expressed in tumor tissues of well-differentiated HCC patients. The mechanism may be that activated transmembrane CXCR7 activates the Wnt signaling pathway through β-arrestin, causing osteopontin expression, which in turn stimulates the ability of tumor cells to metastasize[[56](#_ENREF_56)]. In poorly differentiated tumors, CXCR7 was epigeneti­cally controlled by recombinant suppressor of zeste 12 homolog. Studies have shown in liver cancer cells that the potential upstream regulators of CXCR7 are mainly tumor protein 53, IL-6 and IL-1β[[53](#_ENREF_53)]. CXCR7 is the target protein of miR-101, and miR101 binds to polycomb repressive complex 2 to form a complex that promotes HCC migration and invasion by regulating CXCR7[[64](#_ENREF_64)]. Forkhead box P3 silencing may inhibit the expression of SDF-1/CXCR7 and CXCL11/CXCR7 and may be associated with the inhibition of cell prolifera­tion and migration as well as the induction of apoptosis[[65](#_ENREF_65)]. Plumbagin can abolish SDF-1/CXCR4-CXCR7 activation and inhibit HCC cell proliferation, differentiation, and invasion[[65](#_ENREF_65)]. The mechanism of CXCR7 in HCC cell is shown in Figure 2.

***Angiogenesis of CXCR7 in tumor***

CXCR7 has a potential role in microvascular invasion in HCC, similar to observations in breast and lung tumors[[52](#_ENREF_52)]. CXCR7 plays an important role in HCC migration and invasion of tumor endothelial cells. Chen *et al*[[11](#_ENREF_11)] found that overexpressed CXCR7 could induce human umbilical vein endothelial cell luminal formation and migration and significantly induced the increase in the number of the chicken chorioallantoic membrane secondary and tertiary blood vessels. CXCR7 activation promotes angiogenesis by regulating VEGFA and galectin-3 in HCC *via* the MAPK signaling pathway[[53](#_ENREF_53)]. CXCR7 promotes angiogenesis, and the expression of CXCR7 can induce the secretion of VEGF. VEGF can positively feedback to enhance further the expression of CXCR7. This process occurs through activating the AKT signaling pathway, and the expression of AKT target proteins, including human tumor necrosis factor-alpha, IL-6 and IL-8, is also induced by CXCR7[[11](#_ENREF_11)]. Silencing CXCR7 can reduce tumor endothelial cell migration and invasion in HCC by inhibiting phosphorylated STAT3 at Tyr705 to influence the signaling pathway and its downstream genes MMP-2 and VEGF[[66](#_ENREF_66)]. Plumbagin can inhibit the angiogenesis of HCC by blocking the PI3K/Akt signaling pathway to act on the biological axis of SDF-1/CXCR4-CXCR7[[65](#_ENREF_65)]. The knockdown of CXCR7 significantly inhibits the elevation of VEGF and CD31 induced by TACE, thereby reducing tumor angiogenesis and preventing the growth of HCC[[15](#_ENREF_15)]. The mechanism is shown in Figure 3.

***Role of CXCR7 in tumor prognosis***

However, for HCC, although *in vitro* experiments confirmed that both CXCR4 and CXCR7 can cause liver cancer cell lines to migrate under the action of SDF-1, there is no significant correlation between the expression of CXCR7 and the OS of cancer patients[[50](#_ENREF_50)]. CXCR4 affects the prognosis of HCC patients, but CXCR7 does not[[50](#_ENREF_50)]. The median survival time of the CXCR4-CXCR7+ group, however, was significantly lower than that of the CXCR4-CXCR7- group of HCC patients after hepatectomy, especially during the early stage of follow-up[[54](#_ENREF_54)]. However, CXCR7, particularly combined with alpha-fetoprotein level, was a valuable prognostic indicator for poor prognosis of HCC after hepatectomy, and elevated alpha-fetoprotein levels enhanced the prognostic roles of CXCR7 in time-to-lung metastasis and OS[[54](#_ENREF_54)]. Silencing CXCR7 with RNA interference improved the efficiency of TACE treatment of HCC by extending the survival time of rats[[15](#_ENREF_15)].

**COLORECTAL CANCER**

***Expression in tumor tissue***

The expression of CXCR7 was evaluated in RKO, HCT116, SW480, CT26[[36](#_ENREF_36)] , HT-29 and Caco-2 colorectal cancer (CRC) cells[[13](#_ENREF_13),[37](#_ENREF_37),[38](#_ENREF_38)], and CXCR7 localized to the cytomembrane in HT‑29 cells[[38](#_ENREF_38)]; however, other researchers have found that CXCR7 is absent in HCT116 and HT-29 cells[[37](#_ENREF_37),[39](#_ENREF_39)]. There was a significant upregulation of genes involved in lipid and fatty acid metabolism (*e.g.*, AKR1C3) in SW480-overexpressing CXCR7 cells[[20](#_ENREF_20)] (Table 2).

CXCR7 is expressed in the cytoplasm of CRC cells[[19](#_ENREF_19)], but in HT-29 cells, CXCR7 localized to the cytomembrane[[53](#_ENREF_53)]. The expression of CXCR7 in CRC cells was 4.2 times higher than that in healthy samples[[19](#_ENREF_19)]. Analysis of a group of colonic polyps and chromosomal unstable cancers showed that the early expression of CXCR7 is similar to normal mucosa, but the cancer increases significantly from early to late stage[[36](#_ENREF_36)]. The lower expression levels of CXCR7 in the proximal colon may indicate the role of CXCR7 in microsatellite instability, because colon cancer associated with microsatellite instability mainly occurs in the proximal colon[[47](#_ENREF_47)]. The expression of CXCR7 protein can be detected near the relevant blood vessels of primary CRC and CRC with lung and liver metastases[[52](#_ENREF_52)].

***CXCR7 in the development and metastasis***

CXCR7 is involved in the development, growth and metastasis of CRC[[39](#_ENREF_39)]. When exposed to active oxygen method/diocty l sodium sulfosuccinate, villin-CXCR7 mice showed more severe colitis and tumorigenesis than villin-CXCR4 mice[[23](#_ENREF_23)]. The anti-apoptotic effect of CXCR7 was observed in human CRC, in which silencing the *CXCR7* gene induced cell apoptosis and promoted CRC progression in CRC cells through ERK1/2 and β-arrestin pathway-mediated regulation of proliferating cell nuclear antigen, MMP-2 and caspase-3 expression[[40](#_ENREF_40)]. CXCR7 regulates CRC growth independently of SDF-1[[41](#_ENREF_41)] but binds to the ligand SDF-1 to participate in other CRC processes, such as tumorigenesis and metastasis. CXCL11, another ligand of CXCR7, does not play a role in binding to CXCR7 during these CRC processes[[20](#_ENREF_20)]. CXCR7 affected cell migration *in vitro* in colon cancer HT-29 cells and SW480 cells[[38](#_ENREF_38),[39](#_ENREF_39)], but silencing CXCR7 did not change the migration process nor activate PI3K/Akt or ERK/Ras signaling pathways. CXCR7 does not seem to directly induce cell migration but indirectly causes migration by enhancing cell adhesion[[37](#_ENREF_37)]. In colon cancer, the proliferation of CXCR7 is greater than that of CXCR4, but there is no significant difference between CXCR7 and CXCR4 in migration[[39](#_ENREF_39)]. Additionally, Zabel *et al*[[25](#_ENREF_25)] showed that CXCR7, by mobilizing with β-arrestin instead of Ca2+, regulated human CXCR7+/CXCR4+ lymphoblastoid migration across endothelial monolayers.

When high concentrations of CXCR4 are expressed in circulating cells, it can help them to home to target organs with high expression of SDF-1, while the presence of CXCR7 helps extravasation of vascular endothelial cells, making these circulating cells easier to cross the endothelium, which is conducive to the occurrence of metastasis. In an animal model of CRC induced by LPS, TLR4 promotes the proliferation and migration of CRC cells by regulating the expression of CXCR7 instead of CXCR4[[39](#_ENREF_39)]. Therefore, CXCR4 and CXCR7 seem to play different roles in colon cancer, and the role of CXCR7 in cell migration in colon cancer needs to be further studied.

Remote metastasis of liver and lungs is the main cause of death in CRC patients. CXCR7 expression is significantly associated with lymph nodal metastasis[[39](#_ENREF_39)], lung metastasis[[5](#_ENREF_5)] and advanced Tumor Node Metastasis stage[[42](#_ENREF_42)]. The expression level of CXCR7 in CRC with lymph node metastasis is significantly higher than that of CRC without lymph node metastasis. CXCR7 may be an important predictor of lymph node metastasis in CRC patients[[43](#_ENREF_43)]. CXCR7 appears to be a key factor in the progression of colon cancer metastases in the lungs of mice. This systemic treatment with a CXCR7 antagonist strongly reduced tumor expansion within the lungs of both HT-29- and C26-inoculated mice[[44](#_ENREF_44)]. In addition, in terms of distant metastasis, the expression level of CXCR7 mRNA in lung tissue is 12 times that of liver tissue[[37](#_ENREF_37),[44](#_ENREF_44)]. CXCR7 ligands secreted by cancer cells such as SDF-1 can reach levels sufficient to cause paracrine in the lungs but not in the liver, which may further lead to the progression of tumor metastasis and/or worsening of the disease. The high expression of CXCR7 on the vascular endothelium can be seen in the lung tissue with colon cancer metastasis, so it can be explained that CXCR7 can directly and/or indirectly regulate the development of blood vessels in lung metastases after binding to ligand. Therefore, in lung metastases with colon cancer, unlike liver metastases, the level of SDF-1 is sufficient to trigger these synergistic effects, and the CXCR7 axis may mainly control tumor development in tissues with high expression of SDF-1[[5](#_ENREF_5)]. CXCR7 antagonists have a good effect on lung metastasis of colon cancer but have no effect on liver metastasis[[44](#_ENREF_44)]. However, there was also a correlation between CXCR7 and TLR2 expression in CRC liver metastasis patients, and *TLR2* and *CXCR7* are novel target genes repressed by HIC1[[45](#_ENREF_45)].

*AKR1C3* may be a potential downstream candidate regulatory gene for SDF-1/CXCR7 in the invasion pathway of colon cancer cells and might be a potential survival factor upon SDF-1 stimulation in CXCR7-overexpressing cells; miR-217, miR-218 and their targets may be regulatory molecules of CXCR4 or CXCR7[[20](#_ENREF_20)]. Furthermore, combined expression of TLR4+MD-2+CXCR7 is more likely to result in lymph node metastasis and distant metastasis than each expression alone[[39](#_ENREF_39)]. In the presence of SDF-1 secretion, although CXCR7-expressing colon cancer cell line SW480 was sensitive to 5-fluorouracil, CXCR4-expressing SW480 was more sensitive to 5-fluorouracil[[20](#_ENREF_20)]. The mechanism of CXCR7 in colon cancer cell is shown in Figure 4.

***Angiogenesis of CXCR7 in tumor***

CXCR7 regulates colon cancer angiogenesis by regulating the expression of VEGF through the AKT and ERK pathways[[13](#_ENREF_13)]. CXCR7-silenced Caco-2 and SW480 cells, which were co-cultured with human umbilical vein endothelial cells, inhibited tube formation. CXCR7 regulates colon cancer angiogenesis independently of SDF-1[[41](#_ENREF_41)]. In lung metastasis of CRC, CXCR7 has no regulatory effect on the expression of CXCL8 and VEGF at the transcription level, suggesting that CXCR7 directly regulates the growth of tumor blood vessels by binding to ligand[[44](#_ENREF_44)]. CXCR7 was not modulated by hypoxia or HIF-1α in colon carcinomas[[37](#_ENREF_37)].

***Role of CXCR7 in tumor prognosis***

Patients with positive CXCR7 expression had worse OS and PFS than those with negative CXCR7 expression. Moreover, multivariate analysis with the Cox proportional hazards model demonstrated that the status of CXCR7 expression was an indepen­dent predictive factor for the OS and PFS of CRC patients[[42](#_ENREF_42)]. Patients (neoadjuvant-treated CRC liver metastasis from a phase 2 clinical trial) overexpressing CXCR7 displayed marginal significance with worse median PFS. CXCR7 was not independent of PFS, but programmed death-ligand 1 T-helper cells and CXCR4 were independently correlated with PFS[[45](#_ENREF_45)]. Another study from Kheirelseid *et al*[[47](#_ENREF_47)] showed that after a median follow-up of 15 mo, low CXCR7 expression led to high mortality of CRC, with an average survival of 27 mo, while in CRC patients with high expression of CXCR7, the median survival time was 46 mo. Patients with high expression of CXCR7 in tumor cells lived longer than those with low expression of CXCR7.

**CHOLANGIOCARCINOMA**

***Expression in tumor tissue***

CXCR7 existed in many different cholangiocarcinoma (CCA) cell lines. All intrahepatic (HuCCT-1, SG231 and CCLP1) and extrahepatic (MzCha and TFK1) CCA cell lines expressed CXCR7 at the protein level[[12](#_ENREF_12)]. Its expression level was higher than that of untransformed bile epithelial cells. It is worth noting that the expression of CXCR7 in all cell lines of intrahepatic CCA was higher than that of extrahepatic tumors or human intrahepatic biliary epithelial cells[[12](#_ENREF_12)] (Table 2).

CXCR7 is widely expressed in the cytoplasm of CCA cells[[12](#_ENREF_12)]. The expression of *CXCR7* gene in tumor tissues was higher than that in surrounding non-tumor tissues, the expression level of CXCR7 in larger tumors (> 50 mm) was higher than that in smaller tumors, and the expression of CXCR7 in tumor tissues in moderate/poorly differentiation was higher than expression in well-differentiated tumors[[12](#_ENREF_12)].

***CXCR7 in the development and metastasis***

The combination of CXCR7 and chemokine SDF-1 promotes many related phenotypic characteristics of CCA cells, potentially promoting cancer progression. CXCR7 contributes to SDF-1-induced migration, invasiveness, growth and survival of CCA cells[[12](#_ENREF_12)]. CXCR7 mediates anti-apoptotic effects and induces CCA cell proliferation, and CXCR7 activation is necessary to maintain CCA cell survival. β-arrestin 2 is necessary for SDF-1-induced chemotaxis but dispensable for CXCR7-mediated CCA cell proliferation. Knockdown of CXCR7 expression results in reduced gene expression of MMP-2, MMP-9 and VEGF[[12](#_ENREF_12)]. CXCR7 expression is associated with the maintenance of a stemness-like status in CCA cells. CXCR7 can serve as a factor in the regulation of VEGF secretion and induce angiogenesis in CCA[[12](#_ENREF_12)].

**PANCREATIC ADENOCARCINOMA**

***Expression in tumor tissue***

CXCR7 expression was detected in pancreatic cancer (PAC) cell lines (AsPC-1, MiaPaCa-2, FG, PANC-1, SU.86.86, HS-766 T and BxPC-3)[[58](#_ENREF_58),[62](#_ENREF_62)] (Table 2). The expression of CXCR7 is cytoplasmic, but staining is also visible on the cell surface by immunohistochemistry in PAC[[59](#_ENREF_59)]. In normal pancreatic tissues surrounding the pancreatic cancer, no expression of CXCR7 was seen in either pancreatic acinar or ductal cells. In PAC tissues, strong positive expression of CXCR7 was seen on tumor-associated vascular endothelial cells, but CXCR7 expression was not seen in the vascular endothelium of normal pancreatic tissue around the tumor. Co-expression of CXCR7 and CXCR4 was observed in PAC cells[[62](#_ENREF_62)].

***CXCR7 in development and metastasis***

The CXCR7 receptor may be involved in the progression and metastasis of pancreatic adenocarcinoma and might be useful as an index for evaluating invasiveness[[3](#_ENREF_3),[59](#_ENREF_59),[60](#_ENREF_60)]. The larger the tumor diameter and the lower the differentiation level, the higher the expression level of CXCR7. At the same time, CXCR4 also showed the same expression trend in PAC, suggesting that these two receptors have some functional connection in PAC[[59](#_ENREF_59)]. CXCR7 is related to lymph node metastasis of PAC[[60](#_ENREF_60)]. However, another study found that CXCR7 expression is not associated with tumor size, histological grade, Tumor Node Metastasis stage or distant metastasis in PAC[[60](#_ENREF_60)]. After CXCR7 and SDF-1 activation, β-arrestin 2 induces ERK1/2 phosphorylation, leading to PAC cell proliferation[[62](#_ENREF_62)]. CXCR7 binds to SDF-1 to enhance the migration and invasion of PAC cells by activating the mammalian target of rapamycin and Rho/Rho associated coiled-coil forming protein kinase signaling pathways[[3](#_ENREF_3)]. Pancreatic stellate cells and transforming growth factor β play a role in this process, which also involves CXCR1/CXCL8 signaling[[67](#_ENREF_67)]. Transforming growth factor receptor β upregulated the expression of CXCR4, CXCR4/CXCR7/SDF-1 biological axis activated Hedgehog pathway to activate tumor cells *in vitro* to achieve epithelial mesenchymal transformation[[68](#_ENREF_68)]. The mechanism of CXCR7 in pancreatic adenocarcinoma cell is shown in Figure 5.

***Role of CXCR7 in tumor prognosis***

Through statistical analysis of pancreatic adenocarcinoma, a single analysis showed that there is no relation between the expression of CXCR7 and OS or disease free survival[[59](#_ENREF_59)]. Analysis of the relationship between SDF-1 and CXCR7 expression and prognosis found that the median survival time of the SDF-1+CXCR7+group was 6 mo, and the median survival time of the SDF-1+CXCR7−/SDF-1−CXCR7+ group was 9 mo. The median survival time of the SDF-1−CXCR7− group was 10 mo. The survival time of the SDF-1+CXCR7+ group was significantly shorter than that of the SDF-1+CXCR7−/SDF-1−CXCR7+ group and the SDF-1−CXCR7− group[[60](#_ENREF_60)]. However, several studies have also reported opposite results. Guo *et al*[[3](#_ENREF_3)] conducted a follow-up study on 429 patients with PAC and found that patients with high expression of CXCR7 had a worse prognosis, suggesting that CXCR7 was an independent prognostic factor affecting the survival of PAC patients. Therefore, in order to confirm the value of CXCX7 in the prognosis of pancreatic cancer, a larger, multi-center study involving patients at all stages is necessary. In addition, the specific role of SDF-1/CXCR4/CXCR7 axis in PAC and the relationship between them need to be further studied.

**THE CHEMOKINE (C-X-C MOTIF) RECEPTOR 7 AND CHEMOKINE (C-X-C MOTIF) RECEPTOR 4 INTERACTIONS IN DIGESTIVE TRACT TUMORS**

Whether the effects and dependence on CXCR4 and CXCR7 signaling in some tumors are reflective of individual differences and/or the presence of different subpopulations of tumor cells cannot be answered unequivocally at this point. CXCR7 and CXCR4 may be expressed in distinctive tumor cell populations, such as in breast cancer[[69](#_ENREF_69)] and glioma[[70](#_ENREF_70)]. Currently, in tumors of the digestive system, such as HCC, CRC and PAC, both receptors are expressed in the same cell[[23](#_ENREF_23),[36](#_ENREF_36),[49](#_ENREF_49),[60](#_ENREF_60)]. CXCR4 and CXCR7 have been studied most thoroughly in terms of their presentation and function in colon cancer, and the existence and mechanism of CXCR4 and CXCR7 have not been reported in other digestive system tumors. Confocal live imaging results illustrated the colocalization of CXCR7 and CXCR4 upon SDF-1 internalization and endocytosis[[23](#_ENREF_23)]. CXCR4/CXCR7 heterodimer is highly expressed in 65% of CRC patients, suggesting that this heterodimer may be widely expressed in cancer cells. The CXCR4/CXCR7 heterodimer could enhance SDF-1 mediated signaling; therefore the CXCR4/CXCR7 heterodimer played a stronger role than CXCR4 or CXCR7 homodimers in promoting the tumorigenesis. The CXCR7/CXCR4 heterodimer increased the infiltration of M-myeloid-derived suppressor cells and M2-like macrophages in colonic tissues[[23](#_ENREF_23)].

The CXCR7/CXCR4 heterodimer drove colorectal tumorigenesis by increasing histone demethylation by activating lysine demethylase. The CXCR7/CXCR4 heterodimer translocated much more β-arrestin 1 to the nucleus and then activated histone lysine demethylase to regulate *JMJD2A* expression *via* multiprotein complexes, selectively enriching the promoters of tumor necrosis factor-alpha, IL-6 and c-Myc, which might facilitate the recruitment of histone demethylases, resulting in enhanced local histone demethylation and transcription of these genes. The CXCR4/CXCR7 heterodimer induced elevated levels of JMJD2A, resulting in the demethylation of histones H3K9me3 and H3K36me3. In this process, the role of heterodimer is stronger than that of CXCR7 monomer and CXCR4 monomer[[23](#_ENREF_23)].

Heckmann *et al*[[20](#_ENREF_20)] found that differential expression in SW480-overexpressing CXCR4/CXCR7 cells was similar to that in SW480-CXCR4 cells, indicating that CXCR4 signaling dominates CXCR7 signaling. Very few genes (*e.g.*, troponin C type 1 and *RRAS*) showed SDF-1-dependent upregulation simultaneously in SW480 cells overexpressing CXCR7 and SW480 cells overexpressing CXCR4/CXCR7, with contrasting weak expression of recombinant troponin C type 1 or similar increased expression of RRAS in SW480 cells overexpressing[[20](#_ENREF_20)]. In short, even in similar CRC studies, the research results of different research groups of CXCR4 and CXCR7 are inconsistent. In the future, scientists need to continue research in this field.

**TARGETING CXCR7 WITH ANTIBODIES**

CXCR7 has become increasingly important in various diseases, especially in tumors, and many targeted drugs have been developed against it. Scientists from ChemCentryx filed several patents to cover CCX733, CCX754 and CCX771 as SDF-1/CXCR7 ligands[[70](#_ENREF_71),[71](#_ENREF_72)]. There are now three nanoantibodies targeting CXCR7, namely NB1-3, which all exhibit the substitution properties for SDF-1. NB1 can only partially inhibit the binding of SDF-1 and CXCR7, but NB2 and NB3 can completely inhibit the binding of SDF and CXCR7 by inhibiting the recruitment of SDF-1 to β-arrestin 2[[72](#_ENREF_73)]. The use of small interfering RNA variant (siCXCR7) as well as CCX733 (a CXCR7 antagonist) suppressed the proliferation of long-term estrogen deprivation cells[[73](#_ENREF_74)]. Because SDF-1/CXCR4 has been studied in various diseases for a long time, researchers have studied the role of SDF-1/CXCR4 in cancer cells thoroughly. The antagonist AMD3100 (Plerixafor) designed for the target of CXCR4 has been approved by the United States Food and Drug Administration for the treatment of lymphoma and multiple myeloma[[74](#_ENREF_75)]. Sorafenib combined with AMD3100 prevented the increase of liver tumor fibrosis and improved the efficacy of sorafenib in the treatment of HCC patients[[75](#_ENREF_76)]. The combination of three groups of immunocheckpoint inhibitor anti-programmed cell death protein-1 antibody in the treatment of AMD3100 and sorafenib enhanced the anti-tumor immune response by increasing lymphocyte immune cell infiltration in the necrotic area of HCC, leading to extensive tumor necrosis[[76](#_ENREF_77)]. To our knowledge, no preclinical or clinical studies of therapeutic monoclonal antibody against CXCR7 have been reported.

**CONCLUSION**

In the current review, we demonstrate that CXCR7 plays a key role in tumors of the digestive system. From these studies, we can see that the study of CXCR7 in the digestive system still needs to be continued and that the study of CXCR7 in digestive system tumors mainly focuses on HCC and CRC. CXCR7 has different roles and mechanisms in different organs. Even within the same organ, researchers disagree on the function and mechanism of CXCR7. The complex relationship of biological functions and mechanisms between SDF-1/CXCR4/CXCR7, the localization of CXCR4 and CXCR7 in cells and the functional role of CXCR7 in other types of cancer in digestive tract tumors except CRC have not been studied, so this should form the basis of future research.

**REFERENCES**

1 **Mukaida N**, Sasaki S, Baba T. Chemokines in cancer development and progression and their potential as targeting molecules for cancer treatment. *Mediators Inflamm* 2014; **2014**: 170381 [PMID: 24966464 DOI: 10.1155/2014/170381]

2 **Sawitza I**, Kordes C, Reister S, Häussinger D. The niche of stellate cells within rat liver. *Hepatology* 2009; **50**: 1617-1624 [PMID: 19725107 DOI: 10.1002/hep.23184]

3 **Guo JC**, Li J, Zhou L, Yang JY, Zhang ZG, Liang ZY, Zhou WX, You L, Zhang TP, Zhao YP. CXCL12-CXCR7 axis contributes to the invasive phenotype of pancreatic cancer. *Oncotarget* 2016; **7**: 62006-62018 [PMID: 27542220 DOI: 10.18632/oncotarget.11330]

4 **Ma DM**, Luo DX, Zhang J. SDF-1/CXCR7 axis regulates the proliferation, invasion, adhesion, and angiogenesis of gastric cancer cells. *World J Surg Oncol* 2016; **14**: 256 [PMID: 27716367 DOI: 10.1186/s12957-016-1009-z]

5 **Wang M**, Yang X, Wei M, Wang Z. The Role of CXCL12 Axis in Lung Metastasis of Colorectal Cancer. *J Cancer* 2018; **9**: 3898-3903 [PMID: 30410593 DOI: 10.7150/jca.26383]

6 **Thelen M**, Thelen S. CXCR7, CXCR4 and CXCL12: an eccentric trio? *J Neuroimmunol* 2008; **198**: 9-13 [PMID: 18533280 DOI: 10.1016/j.jneuroim.2008.04.020]

7 **Sun X,** Cheng G, Hao M, Zheng J, Zhou X, Zhang J, Taichman RS, Pienta KJ, Wang J. SDF-1 / CXCR4 / CXCR7 chemokine axis and cancer progression. *Cancer metastasis reviews* 2010; **29:** 709-722 [DOI: 10.1007/s10555-010-9256-x]

8 **Balabanian K**, Lagane B, Infantino S, Chow KY, Harriague J, Moepps B, Arenzana-Seisdedos F, Thelen M, Bachelerie F. The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. *J Biol Chem* 2005; **280**: 35760-35766 [PMID: 16107333 DOI: 10.1074/jbc.M508234200]

9 **Luker KE**, Steele JM, Mihalko LA, Ray P, Luker GD. Constitutive and chemokine-dependent internalization and recycling of CXCR7 in breast cancer cells to degrade chemokine ligands. *Oncogene* 2010; **29**: 4599-4610 [PMID: 20531309 DOI: 10.1038/onc.2010.212]

10 **Rajagopal S**, Kim J, Ahn S, Craig S, Lam CM, Gerard NP, Gerard C, Lefkowitz RJ. Beta-arrestin- but not G protein-mediated signaling by the "decoy" receptor CXCR7. *Proc Natl Acad Sci USA* 2010; **107**: 628-632 [PMID: 20018651 DOI: 10.1073/pnas.0912852107]

11 **Chen Y**, Teng F, Wang G, Nie Z. Overexpression of CXCR7 induces angiogenic capacity of human hepatocellular carcinoma cells via the AKT signaling pathway. *Oncol Rep* 2016; **36**: 2275-2281 [PMID: 27572688 DOI: 10.3892/or.2016.5045]

12 **Gentilini A**, Caligiuri A, Raggi C, Rombouts K, Pinzani M, Lori G, Correnti M, Invernizzi P, Rovida E, Navari N, Di Matteo S, Alvaro D, Banales JM, Rodrigues P, Raschioni C, Donadon M, Di Tommaso L, Marra F. CXCR7 contributes to the aggressive phenotype of cholangiocarcinoma cells. *Biochim Biophys Acta Mol Basis Dis* 2019; **1865**: 2246-2256 [PMID: 31059778 DOI: 10.1016/j.bbadis.2019.04.020]

13 **Li X**, Wang X, Li Z, Zhang Z, Zhang Y. Chemokine receptor 7 targets the vascular endothelial growth factor via the AKT/ERK pathway to regulate angiogenesis in colon cancer. *Cancer Med* 2019; **8**: 5327-5340 [PMID: 31348616 DOI: 10.1002/cam4.2426]

14 **Burns JM**, Summers BC, Wang Y, Melikian A, Berahovich R, Miao Z, Penfold ME, Sunshine MJ, Littman DR, Kuo CJ, Wei K, McMaster BE, Wright K, Howard MC, Schall TJ. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. *J Exp Med* 2006; **203**: 2201-2213 [PMID: 16940167 DOI: 10.1084/jem.20052144]

15 **Zhao ZW**, Fan XX, Song JJ, Xu M, Chen MJ, Tu JF, Wu FZ, Zhang DK, Liu L, Chen L, Ying XH, Ji JS. ShRNA knock-down of CXCR7 inhibits tumour invasion and metastasis in hepatocellular carcinoma after transcatheter arterial chemoembolization. *J Cell Mol Med* 2017; **21**: 1989-1999 [PMID: 28429395 DOI: 10.1111/jcmm.13119]

16 **Yamada K**, Maishi N, Akiyama K, Towfik Alam M, Ohga N, Kawamoto T, Shindoh M, Takahashi N, Kamiyama T, Hida Y, Taketomi A, Hida K. CXCL12-CXCR7 axis is important for tumor endothelial cell angiogenic property. *Int J Cancer* 2015; **137**: 2825-2836 [PMID: 26100110 DOI: 10.1002/ijc.29655]

17 **Xin Q**, Zhang N, Yu HB, Zhang Q, Cui YF, Zhang CS, Ma Z, Yang Y, Liu W. CXCR7/CXCL12 axis is involved in lymph node and liver metastasis of gastric carcinoma. *World J Gastroenterol* 2017; **23**: 3053-3065 [PMID: 28533662 DOI: 10.3748/wjg.v23.i17.3053]

18 **Schrevel M**, Karim R, ter Haar NT, van der Burg SH, Trimbos JB, Fleuren GJ, Gorter A, Jordanova ES. CXCR7 expression is associated with disease-free and disease-specific survival in cervical cancer patients. *Br J Cancer* 2012; **106**: 1520-1525 [PMID: 22531719 DOI: 10.1038/bjc.2012.110]

19 **Hattermann K**, Mentlein R. An infernal trio: the chemokine CXCL12 and its receptors CXCR4 and CXCR7 in tumor biology. *Ann Anat* 2013; **195**: 103-110 [PMID: 23279723 DOI: 10.1016/j.aanat.2012.10.013]

20 **Heckmann D**, Maier P, Laufs S, Li L, Sleeman JP, Trunk MJ, Leupold JH, Wenz F, Zeller WJ, Fruehauf S, Allgayer H. The disparate twins: a comparative study of CXCR4 and CXCR7 in SDF-1α-induced gene expression, invasion and chemosensitivity of colon cancer. *Clin Cancer Res* 2014; **20**: 604-616 [PMID: 24255072 DOI: 10.1158/1078-0432.CCR-13-0582]

21 **Levoye A**, Balabanian K, Baleux F, Bachelerie F, Lagane B. CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. *Blood* 2009; **113**: 6085-6093 [PMID: 19380869 DOI: 10.1182/blood-2008-12-196618]

22 **Décaillot FM**, Kazmi MA, Lin Y, Ray-Saha S, Sakmar TP, Sachdev P. CXCR7/CXCR4 heterodimer constitutively recruits beta-arrestin to enhance cell migration. *J Biol Chem* 2011; **286**: 32188-32197 [PMID: 21730065 DOI: 10.1074/jbc.M111.277038]

23 **Song ZY**, Wang F, Cui SX, Gao ZH, Qu XJ. CXCR7/CXCR4 heterodimer-induced histone demethylation: a new mechanism of colorectal tumorigenesis. *Oncogene* 2019; **38**: 1560-1575 [PMID: 30337690 DOI: 10.1038/s41388-018-0519-2]

24 **Hernandez L**, Magalhaes MA, Coniglio SJ, Condeelis JS, Segall JE. Opposing roles of CXCR4 and CXCR7 in breast cancer metastasis. *Breast Cancer Res* 2011; **13**: R128 [PMID: 22152016 DOI: 10.1186/bcr3074]

25 **Zabel BA**, Wang Y, Lewén S, Berahovich RD, Penfold ME, Zhang P, Powers J, Summers BC, Miao Z, Zhao B, Jalili A, Janowska-Wieczorek A, Jaen JC, Schall TJ. Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4-mediated tumor cell transendothelial migration by CXCR7 ligands. *J Immunol* 2009; **183**: 3204-3211 [PMID: 19641136 DOI: 10.4049/jimmunol.0900269]

26 **Naumann U**, Cameroni E, Pruenster M, Mahabaleshwar H, Raz E, Zerwes HG, Rot A, Thelen M. CXCR7 functions as a scavenger for CXCL12 and CXCL11. *PLoS One* 2010; **5**: e9175 [PMID: 20161793 DOI: 10.1371/journal.pone.0009175]

27 **Odemis V**, Boosmann K, Heinen A, Küry P, Engele J. CXCR7 is an active component of SDF-1 signalling in astrocytes and Schwann cells. *J Cell Sci* 2010; **123**: 1081-1088 [PMID: 20197403 DOI: 10.1242/jcs.062810]

28 **Wu K**, Cui L, Yang Y, Zhao J, Zhu D, Liu D, Zhang C, Qi Y, Li X, Li W, Zhao S. Silencing of CXCR2 and CXCR7 protects against esophageal cancer. *Am J Transl Res* 2016; **8**: 3398-3408 [PMID: 27648130]

29 **Van Rechem C**, Rood BR, Touka M, Pinte S, Jenal M, Guérardel C, Ramsey K, Monté D, Bégue A, Tschan MP, Stephan DA, Leprince D. Scavenger chemokine (CXC motif) receptor 7 (CXCR7) is a direct target gene of HIC1 (hypermethylated in cancer 1). *J Biol Chem* 2009; **284**: 20927-20935 [PMID: 19525223 DOI: 10.1074/jbc.M109.022350]

30 **Qiao Y**, Zhang C, Li A, Wang D, Luo Z, Ping Y, Zhou B, Liu S, Li H, Yue D, Zhang Z, Chen X, Shen Z, Lian J, Li Y, Wang S, Li F, Huang L, Wang L, Zhang B, Yu J, Qin Z, Zhang Y. IL6 derived from cancer-associated fibroblasts promotes chemoresistance via CXCR7 in esophageal squamous cell carcinoma. *Oncogene* 2018; **37**: 873-883 [PMID: 29059160 DOI: 10.1038/onc.2017.387]

31 **Shi A**, Shi H, Dong L, Xu S, Jia M, Guo X, Wang T. CXCR7 as a chemokine receptor for SDF-1 promotes gastric cancer progression via MAPK pathways. *Scand J Gastroenterol* 2017; **52**: 745-753 [PMID: 28281844 DOI: 10.1080/00365521.2017.1300681]

32 **Nambara S**, Iguchi T, Oki E, Tan P, Maehara Y, Mimori K. Overexpression of CXCR7 Is a Novel Prognostic Indicator in Gastric Cancer. *Dig Surg* 2017; **34**: 312-318 [PMID: 27941339 DOI: 10.1159/000452977]

33 **Kim S**, Kim JE, Kim N, Joo M, Lee MW, Jeon HJ, Ryu H, Song IC, Song GY, Lee HJ. Decursin inhibits tumor growth, migration, and invasion in gastric cancer by down-regulating CXCR7 expression. *Am J Cancer Res* 2019; **9**: 2007-2018 [PMID: 31598401]

34 **Cao Y**, Song J, Ge J, Song Z, Chen J, Wu C. MicroRNA-100 suppresses human gastric cancer cell proliferation by targeting CXCR7. *Oncol Lett* 2018; **15**: 453-458 [PMID: 29422961 DOI: 10.3892/ol.2017.7305]

35 **Li N**, Xu H, Ou Y, Feng Z, Zhang Q, Zhu Q, Cai Z. LPS-induced CXCR7 expression promotes gastric Cancer proliferation and migration via the TLR4/MD-2 pathway. *Diagn Pathol* 2019; **14**: 3 [PMID: 30636642 DOI: 10.1186/s13000-019-0780-x]

36 **Rupertus K**, Sinistra J, Scheuer C, Nickels RM, Schilling MK, Menger MD, Kollmar O. Interaction of the chemokines I-TAC (CXCL11) and SDF-1 (CXCL12) in the regulation of tumor angiogenesis of colorectal cancer. *Clin Exp Metastasis* 2014; **31**: 447-459 [PMID: 24493023 DOI: 10.1007/s10585-014-9639-4]

37 **Romain B**, Hachet-Haas M, Rohr S, Brigand C, Galzi JL, Gaub MP, Pencreach E, Guenot D. Hypoxia differentially regulated CXCR4 and CXCR7 signaling in colon cancer. *Mol Cancer* 2014; **13**: 58 [PMID: 24629239 DOI: 10.1186/1476-4598-13-58]

38 **Wang H**, Tao L, Qi KE, Zhang H, Feng D, Wei W, Kong H, Chen T, Lin Q, Chen D. CXCR7 functions in colon cancer cell survival and migration. *Exp Ther Med* 2015; **10**: 1720-1724 [PMID: 26640542 DOI: 10.3892/etm.2015.2748]

39 **Xu H**, Wu Q, Dang S, Jin M, Xu J, Cheng Y, Pan M, Wu Y, Zhang C, Zhang Y. Alteration of CXCR7 expression mediated by TLR4 promotes tumor cell proliferation and migration in human colorectal carcinoma. *PLoS One* 2011; **6**: e27399 [PMID: 22180778 DOI: 10.1371/journal.pone.0027399]

40 **Li XX**, Zheng HT, Huang LY, Shi DB, Peng JJ, Liang L, Cai SJ. Silencing of CXCR7 gene represses growth and invasion and induces apoptosis in colorectal cancer through ERK and β-arrestin pathways. *Int J Oncol* 2014; **45**: 1649-1657 [PMID: 25051350 DOI: 10.3892/ijo.2014.2547]

41 **Kollmar O**, Rupertus K, Scheuer C, Nickels RM, Haberl GC, Tilton B, Menger MD, Schilling MK. CXCR4 and CXCR7 regulate angiogenesis and CT26.WT tumor growth independent from SDF-1. *Int J Cancer* 2010; **126**: 1302-1315 [PMID: 19821487 DOI: 10.1002/ijc.24956]

42 **Yang D**, Dai T, Xue L, Liu X, Wu B, Geng J, Mao X, Wang R, Chen L, Chu X. Expression of chemokine receptor CXCR7 in colorectal carcinoma and its prognostic significance. *Int J Clin Exp Pathol* 2015; **8**: 13051-13058 [PMID: 26722500]

43 **Wang HX**, Tao LY, Qi KE, Zhang HY, Feng D, Wei WJ, Kong H, Chen TW, Lin QS, Chen DJ. Role of CXC chemokine receptor type 7 in carcinogenesis and lymph node metastasis of colon cancer. *Mol Clin Oncol* 2015; **3**: 1229-1232 [PMID: 26807225 DOI: 10.3892/mco.2015.643]

44 **Guillemot E**, Karimdjee-Soilihi B, Pradelli E, Benchetrit M, Goguet-Surmenian E, Millet MA, Larbret F, Michiels JF, Birnbaum D, Alemanno P, Schmid-Antomarchi H, Schmid-Alliana A. CXCR7 receptors facilitate the progression of colon carcinoma within lung not within liver. *Br J Cancer* 2012; **107**: 1944-1949 [PMID: 23169289 DOI: 10.1038/bjc.2012.503]

45 **D'Alterio C**, Nasti G, Polimeno M, Ottaiano A, Conson M, Circelli L, Botti G, Scognamiglio G, Santagata S, De Divitiis C, Nappi A, Napolitano M, Tatangelo F, Pacelli R, Izzo F, Vuttariello E, Botti G, Scala S. CXCR4-CXCL12-CXCR7, TLR2-TLR4, and PD-1/PD-L1 in colorectal cancer liver metastases from neoadjuvant-treated patients. *Oncoimmunology* 2016; **5**: e1254313 [PMID: 28123896 DOI: 10.1080/2162402x.2016.1254313]

46 **Dambly-Chaudière C**, Cubedo N, Ghysen A. Control of cell migration in the development of the posterior lateral line: antagonistic interactions between the chemokine receptors CXCR4 and CXCR7/RDC1. *BMC Dev Biol* 2007; **7**: 23 [PMID: 17394634 DOI: 10.1186/1471-213x-7-23]

47 **Kheirelseid EA**, Miller N, Chang KH, Nugent M, Kerin MJ. Clinical applications of gene expression in colorectal cancer. *J Gastrointest Oncol* 2013; **4**: 144-157 [PMID: 23730510 DOI: 10.3978/j.issn.2078-6891.2013.010]

48 **Xue TC**, Chen RX, Han D, Chen J, Xue Q, Gao DM, Sun RX, Tang ZY, Ye SL. Down-regulation of CXCR7 inhibits the growth and lung metastasis of human hepatocellular carcinoma cells with highly metastatic potential. *Exp Ther Med* 2012; **3**: 117-123 [PMID: 22969855 DOI: 10.3892/etm.2011.358]

49 **Lin L**, Han MM, Wang F, Xu LL, Yu HX, Yang PY. CXCR7 stimulates MAPK signaling to regulate hepatocellular carcinoma progression. *Cell Death Dis* 2014; **5**: e1488 [PMID: 25341042 DOI: 10.1038/cddis.2014.392]

50 **Neve Polimeno M**, Ierano C, D'Alterio C, Simona Losito N, Napolitano M, Portella L, Scognamiglio G, Tatangelo F, Maria Trotta A, Curley S, Costantini S, Liuzzi R, Izzo F, Scala S. CXCR4 expression affects overall survival of HCC patients whereas CXCR7 expression does not. *Cell Mol Immunol* 2015; **12**: 474-482 [PMID: 25363530 DOI: 10.1038/cmi.2014.102]

51 **Xue TC**, Chen RX, Ren ZG, Zou JH, Tang ZY, Ye SL. Transmembrane receptor CXCR7 increases the risk of extrahepatic metastasis of relatively well-differentiated hepatocellular carcinoma through upregulation of osteopontin. *Oncol Rep* 2013; **30**: 105-110 [PMID: 23636305 DOI: 10.3892/or.2013.2442]

52 **Monnier J**, Boissan M, L'Helgoualc'h A, Lacombe ML, Turlin B, Zucman-Rossi J, Théret N, Piquet-Pellorce C, Samson M. CXCR7 is up-regulated in human and murine hepatocellular carcinoma and is specifically expressed by endothelial cells. *Eur J Cancer* 2012; **48**: 138-148 [PMID: 21778049 DOI: 10.1016/j.ejca.2011.06.044]

53 **Zheng K**, Li HY, Su XL, Wang XY, Tian T, Li F, Ren GS. Chemokine receptor CXCR7 regulates the invasion, angiogenesis and tumor growth of human hepatocellular carcinoma cells. *J Exp Clin Cancer Res* 2010; **29**: 31 [PMID: 20380740 DOI: 10.1186/1756-9966-29-31]

54 **Xue TC**, Han D, Chen RX, Zou JH, Wang Y, Tang ZY, Ye SL. High expression of CXCR7 combined with Alpha fetoprotein in hepatocellular carcinoma correlates with extra-hepatic metastasis to lung after hepatectomy. *Asian Pac J Cancer Prev* 2011; **12**: 657-663 [PMID: 21627360]

55 **Xue TC**, Jia QA, Bu Y, Chen RX, Cui JF, Tang ZY, Ye SL. CXCR7 correlates with the differentiation of hepatocellular carcinoma and suppresses HNF4α expression through the ERK pathway. *Oncol Rep* 2014; **32**: 2387-2396 [PMID: 25242412 DOI: 10.3892/or.2014.3501]

56 **Wang L**, Zhang X, Jia LT, Hu SJ, Zhao J, Yang JD, Wen WH, Wang Z, Wang T, Zhao J, Wang RA, Meng YL, Nie YZ, Dou KF, Chen SY, Yao LB, Fan DM, Zhang R, Yang AG. c-Myc-mediated epigenetic silencing of MicroRNA-101 contributes to dysregulation of multiple pathways in hepatocellular carcinoma. *Hepatology* 2014; **59**: 1850-1863 [PMID: 24002871 DOI: 10.1002/hep.26720]

57 **Wu Y**, Tian L, Xu Y, Zhang M, Xiang S, Zhao J, Wang Z. CXCR7 silencing inhibits the migration and invasion of human tumor endothelial cells derived from hepatocellular carcinoma by suppressing STAT3. *Mol Med Rep* 2018; **18**: 1644-1650 [PMID: 29901083 DOI: 10.3892/mmr.2018.9114]

58 **Roy I**, Zimmerman NP, Mackinnon AC, Tsai S, Evans DB, Dwinell MB. CXCL12 chemokine expression suppresses human pancreatic cancer growth and metastasis. *PLoS One* 2014; **9**: e90400 [PMID: 24594697 DOI: 10.1371/journal.pone.0090400]

59 **Gebauer F**, Tachezy M, Effenberger K, von Loga K, Zander H, Marx A, Kaifi JT, Sauter G, Izbicki JR, Bockhorn M. Prognostic impact of CXCR4 and CXCR7 expression in pancreatic adenocarcinoma. *J Surg Oncol* 2011; **104**: 140-145 [PMID: 21520098 DOI: 10.1002/jso.21957]

60 **Liu Z**, Teng XY, Meng XP, Wang BS. Expression of stromal cell-derived factor 1 and CXCR7 ligand receptor system in pancreatic adenocarcinoma. *World J Surg Oncol* 2014; **12**: 348 [PMID: 25407240 DOI: 10.1186/1477-7819-12-348]

61 **Tachezy M**, Zander H, Gebauer F, von Loga K, Pantel K, Izbicki JR, Bockhorn M. CXCR7 expression in esophageal cancer. *J Transl Med* 2013; **11**: 238 [PMID: 24074251 DOI: 10.1186/1479-5876-11-238]

62 **Heinrich EL**, Lee W, Lu J, Lowy AM, Kim J. Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells. *J Transl Med* 2012; **10**: 68 [PMID: 22472349 DOI: 10.1186/1479-5876-10-68]

63 **Yokota S**, Okabayashi T, Rehli M, Fujii N, Amano K. Helicobacter pylori lipopolysaccharides upregulate toll-like receptor 4 expression and proliferation of gastric epithelial cells via the MEK1/2-ERK1/2 mitogen-activated protein kinase pathway. *Infect Immun* 2010; **78**: 468-476 [PMID: 19858308 DOI: 10.1128/iai.00903-09]

64 **Ou X**, Zhang GT, Tian PK, Chen JS, Lin ZW, Xie Y, Wang AH, Liu XP, Liu JK. Forkhead box P3 gene silencing inhibits the expression of chemokines and chemokine receptors associated with cell growth, migration, and apoptosis in hepatocellular carcinoma cells. *Exp Ther Med* 2019; **18**: 1091-1098 [PMID: 31316604 DOI: 10.3892/etm.2019.7658]

65 **Zhong J**, Li J, Wei J, Huang D, Huo L, Zhao C, Lin Y, Chen W, Wei Y. Plumbagin Restrains Hepatocellular Carcinoma Angiogenesis by Stromal Cell-Derived Factor (SDF-1)/CXCR4-CXCR7 Axis. *Med Sci Monit* 2019; **25**: 6110-6119 [PMID: 31415486 DOI: 10.12659/msm.915782]

66 **Zabel BA**, Lewén S, Berahovich RD, Jaén JC, Schall TJ. The novel chemokine receptor CXCR7 regulates trans-endothelial migration of cancer cells. *Mol Cancer* 2011; **10**: 73 [PMID: 21672222 DOI: 10.1186/1476-4598-10-73]

67 **Bertran E**, Caja L, Navarro E, Sancho P, Mainez J, Murillo MM, Vinyals A, Fabra A, Fabregat I. Role of CXCR4/SDF-1 alpha in the migratory phenotype of hepatoma cells that have undergone epithelial-mesenchymal transition in response to the transforming growth factor-beta. *Cell Signal* 2009; **21**: 1595-1606 [PMID: 19586611 DOI: 10.1016/j.cellsig.2009.06.006]

68 **Li X**, Ma Q, Xu Q, Liu H, Lei J, Duan W, Bhat K, Wang F, Wu E, Wang Z. SDF-1/CXCR4 signaling induces pancreatic cancer cell invasion and epithelial-mesenchymal transition in vitro through non-canonical activation of Hedgehog pathway. *Cancer Lett* 2012; **322**: 169-176 [PMID: 22450749 DOI: 10.1016/j.canlet.2012.02.035]

69 **Luker KE**, Gupta M, Luker GD. Imaging chemokine receptor dimerization with firefly luciferase complementation. *FASEB J* 2009; **23**: 823-834 [PMID: 19001056 DOI: 10.1096/fj.08-116749]

70 **Hattermann K**, Held-Feindt J, Lucius R, Müerköster SS, Penfold ME, Schall TJ, Mentlein R. The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects. *Cancer Res* 2010; **70**: 3299-3308 [PMID: 20388803 DOI: 10.1158/0008-5472.CAN-09-3642]

71 **Odemis V**, Boosmann K, Heinen A, Küry P, Engele J. CXCR7 is an active component of SDF-1 signalling in astrocytes and Schwann cells. *J Cell Sci* 2010; **123**: 1081-1088 [PMID: 20197403 DOI: 10.1242/jcs.062810]

72 **Maussang D**, Mujić-Delić A, Descamps FJ, Stortelers C, Vanlandschoot P, Stigter-van Walsum M, Vischer HF, van Roy M, Vosjan M, Gonzalez-Pajuelo M, van Dongen GA, Merchiers P, van Rompaey P, Smit MJ. Llama-derived single variable domains (nanobodies) directed against chemokine receptor CXCR7 reduce head and neck cancer cell growth in vivo. *J Biol Chem* 2013; **288**: 29562-29572 [PMID: 23979133 DOI: 10.1074/jbc.M113.498436]

73 **Ribas R**, Ghazoui Z, Gao Q, Pancholi S, Rani A, Dunbier A, Dowsett M, Martin LA. Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptor-positive breast cancers. *Breast Cancer Res* 2014; **16**: 447 [PMID: 25358600 DOI: 10.1186/s13058-014-0447-1]

74 **Nagasawa T**, Hirota S, Tachibana K, Takakura N, Nishikawa S, Kitamura Y, Yoshida N, Kikutani H, Kishimoto T. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. *Nature* 1996; **382**: 635-638 [PMID: 8757135 DOI: 10.1038/382635a0]

75 **Chen Y**, Huang Y, Reiberger T, Duyverman AM, Huang P, Samuel R, Hiddingh L, Roberge S, Koppel C, Lauwers GY, Zhu AX, Jain RK, Duda DG. Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice. *Hepatology* 2014; **59**: 1435-1447 [PMID: 24242874 DOI: 10.1002/hep.26790]

76 **Chen Y**, Ramjiawan RR, Reiberger T, Ng MR, Hato T, Huang Y, Ochiai H, Kitahara S, Unan EC, Reddy TP, Fan C, Huang P, Bardeesy N, Zhu AX, Jain RK, Duda DG. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice. *Hepatology* 2015; **61**: 1591-1602 [PMID: 25529917 DOI: 10.1002/hep.27665]

**Footnotes**

**Conflict-of-interest statement:** There is no conflict of interest associated with any of the senior author or other coauthors contributed their efforts in this manuscript.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** February 2, 2020

**First decision:** April 9, 2020

**Article in press:**

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): D

Grade E (Poor): 0

**P-Reviewer:** Li CY, Matsuo Y, Rodrigues PM **S-Editor:** Zhang L **L-Editor:** Filipodia **E-Editor:**

**Figure Legends**

C:\Users\Administrator\Desktop\WJGG\Figure 1.tif

**Figure 1 Mechanism of chemokine (C-X-C motif) receptor** 7 **promoting the growth and metastasis of gastric cancer.** Chemokine (C-X-C motif) receptor 7 (CXCR7) affects disease progression by stimulating proliferation, invasion, migration and adhesion of gastric cancer through β-arrestin dependent downstream signaling, including also known as Protein Kinase B, extracellular regulated protein kinases 1/2, p38 mitogen-activated protein kinases, just another kinase 2/ serial advanced technology attachment 3/ cellular-myelocytomatosis, and stress-activated protein kinase pathways by combining with the stromal cell-derived factor-1. CXCR7 inhibits the processing of poly ADP-ribose polymerase and caspase-3 and induces an anti-apoptotic effect. Stromal cell-derived factor-1 promotes the secretion of vascular endothelial growth factor in gastric cancer cells by binding CXCR7, thus causing angiogenesis in gastric cancer. CXCR7: Chemokine (C-X-C motif) receptor 7; Akt: Also known as Protein Kinase B, PKB; ERK1/2: Extracellular regulated protein kinases 1/2; MAPK: Mitogen-activated protein kinases; JAK2: Just another kinase 2; STAT3: Serial advanced technology attachment 3; c-Myc: Cellular-myelocytomatosis; SAPK: Stress-activated protein kinase; SDF-1: Stromal cell-derived factor-1; PARP: Poly ADP-ribose polymerase; VEGF: Vascular endothelial growth factor.

C:\Users\Administrator\Desktop\WJGG\Figure 2.tif

**Figure 2 Mechanism of chemokine (C-X-C motif) receptor** 7 **promoting the growth and metastasis of hepatocellular carcinoma.** Chemokine (C-X-C motif) receptor 7 (CXCR7) contributed to hepatocellular carcinoma growth, including extracellular regulated protein kinases 1/2, and invasiveness *via* the promotion of matrix metalloproteinase 2 expression; CXCR7- mitogen-activated protein kinases-hepatocyte nuclear factor 4α cascade is the general pathway in the differentiation of hepatocellular carcinomas. Activated transmembrane CXCR7 activates the Wnt signaling pathway through β-arrestin, causing osteopontin expression, which in turn stimulates the ability of tumor cells to metastasize. Several regulators, including tumor protein 53, interleukin-6 and interleukin-1β, are potential upstream regulators of CXCR7-induced signaling. CXCR7: Chemokine (C-X-C motif) receptor 7; ERK1/2: Extracellular regulated protein kinases 1/2; MMP-2: Matrix metalloproteinase 2; MAPK: Mitogen-activated protein kinases; HNF4α: Hepatocyte nuclear factor 4α; OPN: Osteopontin; TP53: Tumor protein 53; IL-6: Interleukin-6; IL-1β: Interleukin-1β.

C:\Users\Administrator\Desktop\WJGG\Figure 3.tif

**Figure 3 Mechanism of chemokine (C-X-C motif) receptor** 7 **in angiogenesis of hepatocellular carcinoma.** Chemokine (C-X-C motif) receptor 7 (CXCR7) activation promotes angiogenesis by regulating vascular endothelial growth factor and galectin-3 in hepatocellular carcinoma *via* the mitogen-activated protein kinases signaling pathway. This process occurs through activating the also known as Protein Kinase B signaling pathway, and the expression of also known as Protein Kinase B target proteins, including human tumor necrosis factor-alpha, interleukin-6, and interleukin-8, is also induced by CXCR7; CXCR7 can promote tumor endothelial cells migration and invasion in hepatocellular carcinomas by phosphorylated serial advanced technology attachment 3 at Tyr705 to influence the signaling pathway and its downstream genes matrix metalloproteinase 2 and vascular endothelial growth factor. CXCR7: Chemokine (C-X-C motif) receptor 7; VEGF: Vascular endothelial growth factor; MAPK: Mitogen-activated protein kinases; Akt: Also known as Protein Kinase B, PKB; TNF‑α: Human tumor necrosis factor-alpha; IL-6: Interleukin-6; IL-8: Interleukin-8; TEC: Tumor endothelial cells; STAT3: Serial advanced technology attachment 3; MMP-2: Matrix metalloproteinase 2; VEGF: Vascular endothelial growth factor.

C:\Users\Administrator\Desktop\WJGG\Figure 4.tif

**Figure 4 Mechanism of chemokine (C-X-C motif) receptor** 7 **promoting colorectal cancer growth and metastasis.** Chemokine (C-X-C motif) receptor 7 (*CXCR7*) gene induced cell anti-apoptosis and promoted colorectal cancer progression in colorectal cancer cells through extracellular regulated protein kinases 1/2 and β-arrestin pathway-mediated regulation of proliferating cell nuclear antigen, matrix metalloproteinase 2 and caspase-3 expression. miR-217, miR-218 and their targets may be regulatory molecules of Chemokine (C-X-C motif) receptor 4 (CXCR4) or CXCR7. The CXCR7/CXCR4 heterodimer translocated much more β-arrestin 1 to the nucleus and then activated histone lysine demethylase to regulate *JMJD2A* expression *via* multiprotein complexes, selectively enriching the promoters of human tumor necrosis factor-alpha, interleukin-6, and cellular-myelocytomatosis, which might facilitate the recruitment of histone demethylases, resulting in enhanced local histone demethylation and transcription of these genes. The CXCR7/CXCR4 heterodimer induced high levels of JMJD2A, leading to demethylation of histones H3K9me3 and H3K36me3 compared with the CXCR7 monomer and CXCR4 monomer. CXCR7: Chemokine (C-X-C motif) receptor 7; ERK1/2: Extracellular regulated protein kinases 1/2; PCNA: Proliferating cell nuclear antigen; MMP-2: Matrix metalloproteinase 2; CAS-3: Caspase-3; CXCR4: Chemokine (C-X-C motif) receptor 4; TNF‑α: Human tumor necrosis factor-alpha; IL-6: Interleukin-6; *c-Myc*: Cellular-myelocytomatosis.

C:\Users\Administrator\Desktop\WJGG\Figure 5.tif

**Figure 5 Mechanism of chemokine (C-X-C motif) receptor** 7 **promoting the growth and metastasis of pancreatic cancer.** After chemokine (C-X-C motif) receptor 7 and stromal cell-derived factor-1 activation, β-arrestin 2 induces extracellular regulated protein kinases 1/2 phosphorylation, leading to pancreatic cancer cell proliferation. Chemokine (C-X-C motif) receptor 7 binds to stromal cell-derived factor-1 to enhance the migration and invasion of pancreatic cancer cells by activating the mammalian target of rapamycin and Rho/Rho associated coiled-coil forming protein kinase signaling pathways. CXCR7: Chemokine (C-X-C motif) receptor 7; SDF-1: Stromal cell-derived factor-1; ERK1/2: Extracellular regulated protein kinases 1/2; mTOR: Mammalian target of rapamycin; Rho/ROCK: Rho/Rho associated coiled-coil forming protein kinase.

**Table 1 Stromal cell-derived factor-1/chemokine (C-X-C motif) receptor 7 impact in digestive tract tumor**

|  |  |  |
| --- | --- | --- |
| **Cancer** | **Biological/clinical effects** | **Ref.** |
| Esophageal cancer | Proliferation, metastasis, prognosis | Wu *et al*[[28](#_ENREF_28)]; Van Rechem *et al*[[29](#_ENREF_29)]; Qiao *et al*[[30](#_ENREF_30)] |
| Gastric cancer | Proliferation, metastasis, prognosis, angiogenesis | Ma *et al*[[4](#_ENREF_4)]; Xin *et al*[[17](#_ENREF_17)]; Shi *et* *al*[[31](#_ENREF_31)]; Nambara *et al*[[32](#_ENREF_32)]; Kim *et al*[[33](#_ENREF_33)]; Cao *et al*[[34](#_ENREF_34)]; Li *et al*[[35](#_ENREF_35)] |
| Colorectal | Proliferation, metastasis, angiogenesis | Wang *et al*[[5](#_ENREF_5)]; Li *et al*[[13](#_ENREF_13)]; Heckmann *et al*[[20](#_ENREF_20)]; Song *et al*[[23](#_ENREF_23)]; Rupertus *et al*[[36](#_ENREF_36)]; Romain *et al*[[37](#_ENREF_37)]; Wang *et al* [[38](#_ENREF_38)]; Xu *et al*[[39](#_ENREF_39)]; Li *et al*[[40](#_ENREF_40)]; Kollmar *et al*[[41](#_ENREF_41)]; Yang *et al*[[42](#_ENREF_42)]; Wang *et al*[[43](#_ENREF_43)]; Guillemot *et al*[[44](#_ENREF_44)]; D'Alterio *et al*[[45](#_ENREF_45)]; Dambly-Chaudière *et al*[[46](#_ENREF_46)]; Kheirelseid *et al*[[47](#_ENREF_47)] |
| Hepatocellular carcinoma | Proliferation, metastasis, prognosis, angiogenesis, differentiation | Chen *et al*[[11](#_ENREF_11)]; Zhao *et al*[[15](#_ENREF_15)]; Xue *et al*[[48](#_ENREF_48)]; Lin *et al*[[49](#_ENREF_49)]; Neve Polimeno *et al*[[50](#_ENREF_50)]; Xue *et al*[[51](#_ENREF_51)]; Monnier *et al*[[52](#_ENREF_52)]; Zheng *et al*[[53](#_ENREF_53)]; Xue *et al*[[54](#_ENREF_54)]; Xue *et al*[[55](#_ENREF_55)]; Wang *et al*[[56](#_ENREF_56)]; Wu *et al*[[57](#_ENREF_57)] |
| Pancreatic adenocarcinoma | Proliferation, metastasis, prognosis | Guo *et al*[[3](#_ENREF_3)]; Roy *et al*[[58](#_ENREF_58)]; Gebauer *et al*[[59](#_ENREF_59)]; Liu *et al*[[60](#_ENREF_60)] |
| Cholangiocarcinoma | Proliferation, angiogenesis | Gentilini *et al*[[12](#_ENREF_12)] |

**Table 2 Expression of chemokine (C-X-C motif) receptor 7 in different cancer cell lines**

|  |  |  |
| --- | --- | --- |
| **Cancer** | **Cell lines** | **Ref.** |
| Gastric cancer | HGC-27, MGC-803, BGC-823, SGC-7901, MKN-28 | Ma *et al*[[4](#_ENREF_4)]; Shi *et al*[[31](#_ENREF_31)] |
| Colorectal cancer | RKO, HCT116, SW480, CT26, HT-29, Caco-2 | Li *et al*[[13](#_ENREF_13)]; Heckmann *et al*[[20](#_ENREF_20)]; Rupertus *et al*[[36](#_ENREF_36)]; Wang *et al*[[38](#_ENREF_38)]; Romain *et al*[[37](#_ENREF_37)]; Xu *et al*[[39](#_ENREF_39)]; Li *et al*[[40](#_ENREF_40)] |
| Hepatocellular carcinoma | HCCLM3, L02, QSG7701, QGY-7703, Hep3B, SMMC‑7721, MHCC97‑L, HepG2, Huh7, 97H, LM3, LM6,SNU449, SNU475 | Chen *et al*[[11](#_ENREF_11)]; Xue *et al*[[48](#_ENREF_48)]; Lin *et al*[[49](#_ENREF_49)]; Neve Polimeno *et* *al*[[50](#_ENREF_50)]; Zheng *et al*[[53](#_ENREF_53)] |
| Cholangiocarcinoma | HuCCT-1, SG231, CCLP1, MzCha, TFK1 | Gentilini *et al*[[12](#_ENREF_12)] |
| Pancreatic cancer | AsPC-1, MiaPaCa-2, PANC-1, SU86.86, HS-766 T, BxPC-3, FG, T3M4 | Guo *et al*[[3](#_ENREF_3)]; Roy *et al*[[58](#_ENREF_58)]; Heinrich *et al*[[62](#_ENREF_62)] |